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ABSTRAK 
 
  Denggi disebarkan melalui gigitan nyamuk yang dijangkiti oleh salah satu 
daripada empat serotype virus denggi. Antara sasaran terapeutik yang mantap 
sepanjang penemuan drug anti-denggi, NS2B-NS3 protease adalah agak popular oleh 
kerana peranannya dalam pengeluaran virus matang dan memainkan peranan penting 
dalam mengekalkan kebolehjangkitan. Kerja-kerja di dalam tesis ini memerihalkan 
kajian komputer dan eksperimen dalam reka bentuk dan sintesis NS2B-NS3 protease 
baharu daripada struktur semulajadi seperti lawsone dan asid ferulik. Dalam kes 
naphthoquinone kelas sebatian, adalah difahamkan dari dok pengajian yang 
penubuhan molekul fleksibiliti boleh membawa kepada lebih ketat mengikat 
sebatian. Pada masa yang sama, rasional scaffold mengurangkan pendekatan telah 
dilaksanakan bertujuan untuk mengurangkan saiz molekul untuk membangunkan 
sebatian berat molekul yang rendah juga terbukti berhasil di laluan reka bentuk 
daripada anthrakuinon naptokuinon. Dok molekul yang terperinci dan analisis 
interaksi membawa kepada ramalan bahawa sabatian vanilin (VAN) dan lawsone 
(LAW) boleh menjadi aktif secara eksperimental.  Cerakin enzim kedua-dua sebatian 
tersebut terhadap NS2B-NS3 protease kemudiannya membuktikan bahawa vanilin 
dan lawsone adalah aktif dengan IC50 masing-masing sebanyak 108 µM dan 878 µM. 
Reka bentuk tambahan berasaskan dok molekul membawa kepada sintesis lapan 
belas sebatian. Sebatian yang terpilih adalah milik tiga kelas kimia berbeza iaitu 
binaptokuinone, aminonaptokuinone dan asid α-(arilamino) sinamik. Semua sebatian 
yang disintesis telah dicirikan oleh FTIR, NMR 1H dan 13C dan Spektroskopi Jisim 
 xii 
(MS). Akhir sekali, kajian perencatan enzim membawa kepada pengenalpastian 
sebatian SS-2 dan SS-5 yang menunjukkan  IC50 masing-masing sebanyak 37.92 µM 
dan 0.0065 µM. Secara keseluruhan, pendekatan reka bentuk berasaskan struktur dan 
pengesahan lanjut melalui eksperimen dalam kerja ini berjaya membuktikan konsep 
reka bentuk drug yang rasional. 
 xiii 
STRUCTURE BASED DESIGN AND SYNTHESIS OF POTENTIAL 
DENGUE VIRUS NS2B-NS3 PROTEASE INHIBITORS 
 
 
ABSTRACT 
 
  Dengue is transmitted by the bite of a mosquito infected with one of the five 
dengue virus serotypes. As far as anti-dengue drug discovery is concerned, among 
few established therapeutic targets, NS2B-NS3 protease is quite popular due to its 
role in production of mature viruses and plays a key role in maintaining infectivity. 
The work in this thesis described the computational and experimental studies in the 
design and synthesis of novel NS2B-NS3 protease from natural scaffolds such as 
lawsone and ferulic acid. In the case of naphthoquinone class of compounds, it was 
understood from docking studies that incorporation of molecular flexibility could 
lead to tighter binding compounds. Simultaneously, rational scaffold minimizing 
approach was undertaken with an aim to reduce molecule size to develop low 
molecular weight compounds also proved fruitful in the design pathway from 
anthraquinone to naphthoquinone. Detailed molecular docking and interaction 
analysis led to the prediction that compounds vanillin (VAN) and lawsone (LAW) 
could be experimentally active. Subsequent enzymatic assay of these two compounds 
against NS2B-NS3 protease proved that vanillin and lawsone were active with IC50 
of 108 µM and 878 µM, respectively. Further design based on molecular docking 
studies led to the synthesis of derivatives of lawsone and vanillin. The selected 
compounds belonged to three distinct chemical classes, binaphthoquinones, 
aminonaphthoquinones and α-(arylamino) cinnamic acids. All the synthesized 
compounds were characterized by FTIR, proton and 13C NMR, as well as mass 
spectroscopy. Finally, enzymatic inhibition studies led to the identification 
compound SS-2 (binaphthoquinone scaffold) and SS-5 (amino naphthoquinone) 
 xiv 
which showed IC50 of 37.92 µM and 0.0065 µM respectively. Overall, the structure 
based design approach and subsequent experimental validation through the present 
work successfully proved the concept of computer aided drug design.
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CHAPTER 1: INTRODUCTION 
 
1.1 Statement of the Problem 
Arthropod borne infection like dengue is a major concern to the world and a leading 
cause of illness and death in the tropical and subtropical regions of the world. It is 
estimated that 3.9 billion people in 128 countries are at risk of infection with dengue 
viruses (Brady et al. (2012)). Although the scale of dengue infection has not reached 
pandemic proportion, in Malaysia, from 10 to 16 January 2016, there were 3,500 
cases of dengue reported (Hemisphere, (2016)). In Malaysia, there were 43347 cases 
of which 13081 were serologically confirmed (Omar et al. (2016)). Whilst in 
neighboring country, Indonesia, there were 500,000 patients being hospitalized in 
2014 (Karyanti et al. (2014)). Between 2006 and 2012,  India reported an annual 
average of 20,474 dengue cases (Shepard et al. (2014)) .  
Dengue cases have increased drastically in the last 50 years due to the growth of 
population and uncontrolled urbanization. This further compounded by the improved 
transportation and ease of travelling both locally and internationally which have in 
one way or the other, facilitated the spread of dengue virus as well (Murray et al. 
(2013)). 
Thus, there is indeed an urgent need to give due attention and put sufficient 
research fund in the development of effective antiviral agent for the treatment of 
dengue. 
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1.2 Objectives 
Based on the problem statement mentioned above, the aim of this study is to develop 
novel inhibitors of DENV2 NS2B-NS3 protease. Specifically, the objective of this 
work are to: 
1. Investigate the binding mode of important inhibitors of DENV2 NS2B-NS3 
protease using molecular docking studies, 
2. Design novel protease inhibitors through results obtained from molecular docking 
studies, 
3. Synthesize the designed protease inhibitor molecules, 
4. Conduct bioassay studies to evaluate the inhibition potential of the synthesized 
compounds against protease. 
 
1.3 The Structure and Genome of Dengue Virus 
Dengue fever is caused by infection from any one of the five serotype of the virus 
(DENV1-5) that may be transmitted to human by a day-biting female mosquito 
Aedes aegypti (Henchal & Putnak, (1990)). The virus is a sphere-shaped virus with 
an envelope. It comprises of a single, positive strand RNA genome that is packed by 
three structural proteins and a lipid bilayer. The structural proteins are named as 
capsid, C; membrane associated, M and an envelope, E (Kuhn et al. (2002); Rey, 
(2003)). The RNA of dengue virus consists of a 5'-untranslated region (UTR), a 
single open reading frame (ORF) and 3'-untranslated region (UTR) (Dong, Zhang, & 
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Shi, (2008)). These three structural proteins are encoded by 5'terminus of the open 
reading frame of the genome. The remainder of the ORF encodes seven nonstructural 
proteins i.e.NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5 (Fig.1.1). 
 
 
Figure 1.1 Schematic diagram of the dengue virus genome and polyprotein (Aruna, 
2014). 
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1.3.1 Life cycle of dengue virus and role of important proteins 
The life cycle of the dengue virus starts with the attachment and binding of the 
virions on the host cell surface, followed by entry into the cell by endocytosis and 
endosome formation (Fig.1.2).  
 
Figure 1.2 Life cycle of Dengue virus. (Aruna, 2014) 
 
After entry of virus cell and subsequent uncoating of the nucleocapsid, the RNA 
molecule is translated into a single polyprotein (Miller, Kastner, Krijnse-Locker, 
Bühler, & Bartenschlager, (2007)). During this process, the signal and stop-transfer 
sequences of the polyprotein direct its back-and-forth translocation across the 
endoplasmic reticulum (ER) membrane. The polyprotein is processed by proteases 
into three structural proteins (C, prM, and E) and seven nonstructural (NS) proteins 
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(NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5). The E protein is glycosylated at 
amino acid residue Asn67 and Asn153 to obtain appropriate folded conformation of 
the protein (Chambers et al. (1995)). Other potential N-linked glycosylation sites are 
located in prM at position 7, 31, and 52 and within NS1 at position 130 and 207 (Luo 
et al. (2008); Wu et al. (2003)). Once the proteins are translated and folded, the non-
structural proteins initiate replication of the viral genome (Miller et al. (2007)). 
 
The newly synthesized RNA is subsequently packed by the C protein to form a 
nucleocapsid. The prM and E proteins form heterodimers that are oriented into the 
lumen of the ER which will then be associated into trimers. These oligomeric 
interactions are believed to induce a curved surface lattice, which helps in virion 
budding (Chambers, (1990); Falgout et al. (1991)). 
 
Interestingly, encapsulation of nucleocapsid during virus assembly is not pivotal 
as the genesis of capsid-less subviral particles (Bera et al. (2007)); Clum et al.,  
(1997)); Gorbalenya et al., (1993); Shiryaev et al. (2007)). Detailed structural 
analysis of newly formed virions has revealed that a single virion consist of 180 
prM/E heterodimers which protrude outward from the surface of the virus as 60 
trimeric spikes (Aleshin et al., 2007; Erbel et al. 2006; Wu et al., (2005)). The 
immature particles formed in the ER continue to mature during their journey through 
the secretory pathway. The slightly acidic pH (*5.8–6.0) of the trans-Golgi network 
(TGN) leads to dissociation of the prM/E heterodimers, which further initiates the 
formation of 90 dimers that lie flat on the viral surface, with prM capping the fusion 
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peptide of the E protein. This structural reorganization of the glycoproteins leads to 
cleavage of prM  by the cellular endoprotease furin (Xu et al. (2005); Yamashita et 
al. (2008); Yao et al. (1997)). Furin cleavage happens at a Arg-X-(Lys/Arg)-Arg 
(where X is any amino acid) recognition sequence and formation of membrane-
associated M and a "pr" peptide takes place. A recent study has shown that the pr 
peptide remains attached with the virion until the virus is secreted to the extracellular 
environment (Xu et al. (2005)). Both prM protein and pr peptide are believed to act 
as chaperones that stabilizes the E protein during passage through the secretory 
pathway. This in turn, prevents premature conformational changes of the E protein 
that may lead to membrane fusion. After dissociation of the pr peptide, mature 
virions are formed which then released to infect new cells. 
 
1.3.2 Dengue virus NS2B-NS3 protease 
The proteases class of enzymes carry out protein hydrolysis at an accelerated rate 
although with absolute specificity which ensures prevention of uncontrolled 
proteolysis of the proteins for any organism. Proteases can be further divided into 
serine, cysteine, aspartic, threonine and metallo proteases. The catalytic nucleophile 
(hydroxyl group) of serine in serine protease active site helps in the degradation of 
proteins. Protease binds with the substrate in a specific manner that is represented by 
Schechter and Berger system of nomenclature (Berger A. (1967)) (Fig. 1.3). 
 7 
 
              Fig 1.3 Schehter and Berger system of nomenclature. 
 
In this method of nomenclature, the amino acid residues (or side chains) of 
substrate are labeled from the N to C terminus as 
Pn,.......,P3,P2,P1,P1’,P2’,P3’,........Pn’ and the corresponding binding sub sites of the 
enzyme are labeled as Sn,.......,S3, S2, S1, S1’,S2’,S3’,........Sn’. The peptide bond 
hydrolysis is carried out between P1,P1’ and the bond is called the scissile bond (Fig. 
1.3).  
In this case, the P1 residue of the substrate is called the primary specificity 
residue. The specificity and selectivity of a protease primarily depends on the nature 
of the P1 residue. Serine proteases are further classified as elastase-like (small 
hydrophobic residues at P1), trypsin-like (positively charged residues/basic residues 
at P1) or chymotripsin-like (large hydrophobic residues at P1). 
The N-terminal domain of NS3 (aa 1–169) is a chymotrypsin like serine protease 
that cleaves the viral polyprotein (Chambers et al. (1990)) (Fig.1.4). The NS3 
protease requires the NS2B cofactor to function as an active enzyme (Falgout et al, 
 8 
1991). NS2B is a14 kDa protein that consists of three domains: two trans-membrane 
regions located at the N and C terminals and a central region of 47 amino acids 
(amino acids 49–96) which acts as a protein cofactor of the NS3 protease (Clum et 
al. (1997)). The dengue virus NS3 protein is neither soluble nor catalytically active 
as a protease in vitro, suggesting that it does not fold properly without the NS2B 
protein(Kim et al. (2013); T. Xu et al. (2005)).  
 
Figure 1.4 The structure of NS2B-NS3 complex and orientation of active site 
residues: Asp75, His51 and Ser135 (Wichapong, (2010)). 
 
1.3.3 Proteolytic mechanism of NS2B-NS3 protease 
DENV NS2B-NS3 protease is a member of serine protease family. These proteases 
are a class of proteolytic enzymes, which are characterized by the presence of 
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reactive serine residues. It has a catalytic triad containing histidine, serine and 
aspartic acid residues. As shown in Fig. 1.4, the active site’s geometry as well as the 
proteolytic activity is governed by hydrogen bonding interaction of the catalytic 
residues. The hydrogen bonding networks generate a very reactive oxyanion species 
on serine that attacks the carbonyl group of the peptide bond in the substrate which 
leads to the formation of a tetrahedral intermediate, in which the carbonyl carbon of 
the substrate changes from sp2 to sp3. This process converts serine to alkoxide 
(ionised serine) through a  charge relay system (Fig. 1.5) (Melino et al., 2007). 
 
Fig. 1.5 Charge relay system for activation of an active site serine residue. 
 The active site of serine (activated nucleophile) then attacks the carbonyl group of 
the scissile amide bond. This intermediate undergoes rearrangement to release N-
terminal peptide leaving C-terminal attached to serine. Subsequent hydrolysis by the 
water molecule near the active site releases C-terminal peptide from serine which 
regenerates the catalytic triad for its next cycle of proteolysis (Fig. 1.6). 
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Figure 1.6 Mechanism of serine protease (Timiri, Sinha, & Jayaprakash, (2016)). 
 
1.4 NS2B-NS3 Protease Inhibitors 
1.4.1 Peptide inhibitors 
The discovery of dengue NS2B-NS3 protease inhibitors were initially based on the 
information obtained from kinetic profiling of non-prime substrates. (Li et al. (2005)) 
(Frecer et al., (2010), Yang et al. (2011), Katzenmeier et al., (2004)).These efforts 
were quite challenging as the enzyme has a solvent-exposed, shallow active site and 
is dependent on the selectivity for substrates containing basic amino acids (arginine 
and lysine) at P1 and P2 positions (Cregar-Hernandez et al. (2011)). Nevertheless, 
many peptidic inhibitors have been discovered to have NS2B-NS3 protease 
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inhibition activities (Behnam et al. (2016); Nitsche et al.(2012), Nitsche et al. (2013), 
Rothan et al. (2012), Prusis et al. (2013), Xu et al. (2012)). 
 
Li et al. (2005) designed synthetic peptides from the substrate kinetic profiling 
attached to electrophilic war-heads of serine proteases inspired by earlier work 
(Powers, et al., (2002)). Starting from two tetra-peptides (Bz-Nle-Lys-Arg-Arg-OH 
and Bz-Nle-Lys-Thr-Arg-OH)* sequences  a series of ten inhibitors with different 
electrophilic warhead were synthesized. Peptides having boronic acid warhead (Bz-
NIe-Lys-Arg-Arg-B(OH)2) was shown to have an excellent inhibition at a 
concentration of Ki of 43nM(Yin et al. (2006)).  
Tables 1.1 and 1.2 summarize some sequence and activity of the key peptide 
inhibitors which are being reported in literature.  
Table 1.1 The activity of peptides against DENV2 NS2B-NS3 protease  
Peptide Activity (M) 
Bz-Nle-Lys-Arg-Arg-H Ki= 5.8 
Bz-Nle-Lys-Arg-Arg-B(OH)2 Ki= 0.043 
Bz-Nle-Lys-Arg-Arg-CF3 Ki=0.85 
Bz-Phe-Lys-Arg-Arg-H Ki= 6.8 
Bz-Lys-Arg-Arg-H Ki = 1.5 
Ph-Ac-Lys-Arg-Arg-H IC50 = 6.7 
2-cyano-N-cyclopropylbut-2-eanmide-Arg-Lys-Nle-NH2 Ki= 4.9 
Ac-Phe-Ala-Ala-Gly-Arg-Arg-H Ki = 16.3 
Retrocyclin-1 IC50= 21.4 
Protegrin-1 Ki= 5.85 
Latarcin 1 IC50 = 12.7 
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Prusis and co-workers implemented a rational step-wise substitution/deletion of 
charged amino acids from prime site in order to achieve drug-likeness. A peptide 
inhibitor, WYCW-NH2 showed significant protease inhibition with an IC50 of 4.8M 
(Prusis et al. (2013)). Molecular modeling studies revealed that the N-terminal of the 
inhibitors interacted with Asp75 residue of the active site. The first two amino acids 
of the peptide interacted with S3 and S4 pockets, respectively while the fourth amino 
acid was found to established pi-pi stacking interaction with Tyr161 of S1 pocket. 
Table 1.2 Active modified peptides having inhibition against NS2B-NS3 protease. 
Inhibitor Ki value (µM) 
Ac-Phe-Ala-Ala-Gly-Arg-Arg-CHO 16 ± 3 
Ac- Phe-Ala-Ala-Gly-Arg-Arg -αketo-Ser-Leu-CONH2 47 ± 3 
Ac-Thr-Thr-Ser-Thr-Arg-Arg -αketo-SL-CONH2 220 ± 55 
Ac- Thr-Thr-Ser-Thr -Arg-Arg -αketo-GTGN-CONH2 368 ± 47 
Ac-Arg-ThrSer-Lys -Lys-Arg -CONH2 12.14 
Ac- Lys -Lys-Arg -CONH2 22.31 
Ac- Phe-Ala-Ala-Gly-Arg- Lys -CONH2 25.87 
Ac- Thr-Thr-Ser-Thr-Arg-Arg -CONH2 45.96 
Ac-EV Lys -Lys-Gln Arg -CONH2 66.68 
Ac-Lys-Arg-CONH2 121.53 
Ac-Gly-Lys-Arg-CONH2 152.30 
Ac-Ser-Lys -Lys-Arg-CONH2 187.60 
 
Bioavailability and metabolic stability are two major challenges that have to be 
addressed in the development of linear peptide as an inhibitor. The problems were 
addressed by designing cyclic peptides which have the advantage of good 
permeability and metabolic stability when compared with linear peptides (Horton, et 
al., (2002)). 
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Various cyclic peptides were already being evaluated against DENV NS2B-NS3 
protease and in support this case, four examples could be highlighted (Fig.1.7). 
Kalata B1 is a plant-based cyclopeptide (Fig.1.7a) and its derivatives (Fig. 1.7a(i) 
and (ii)) were synthesized and evaluated against dengue protease (Gao, et al., 
(2010)). They were found to inhibit DENV2 protease with an IC50 of 4.3 µM and 9.3 
µM respectively. 
In a different study, retrocyclin-1 (Fig. 1.7b) was tested for DENV NS2B-NS3 
protease activity at different temperatures. The (IC50) values at 40
oC, 37oC and 28oC 
were found to be 14.1, 21.4 and 46.1 µM respectively. Retrocyclin-1 also inhibited 
DENV2 replication in Vero cells (Rothan et al. (2012)). 
 
The third example, conotoxin MrIA (Fig. 1.7c), is a peptide from Conus 
marmoreus which was found to inhibit DENVNS2B-NS3 protease significantly (Xu 
et al. 2012). Synthetic Protegrin-1 (Fig. 1.7d) is another cyclic peptide which was 
shown to have activity against DENV NS2B-NS3 protease. It was found to inhibit 
the replication of DENV2 in MK2 cells and DENV2 NS2B-NS3 protease with an 
IC50 of 11.7 µM (Rothan et al. (2012)). In that study, three concentrations of PG-1 
were used to test the peptide stability and its capability to reduce dengue viral 
replication in MK2 cell lines. The results clearly explain that the viral copy number 
got reduced with increasing concentrations of protegrin-1. In addition to that, the 
highest inhibition percentage was observed when the PG-1 concentration was 
12.5 μM at 24, 48 and 72 hrs. 
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Figure 1.7 Cyclic peptides which are active against NS2B-NS3 protease. 
 
1.4.2 Peptide-conjugates 
Peptides attached to small organic molecules could imitate the natural substrates and 
may be a potential inhibitor for a targeted protein. The strategy behind this approach 
was to combine the drug-likeness of small molecules with the specificity of 
substratemimicking peptides. Thiazolidine and rhodanine (cap) scaffolds were 
conjugated with substrate mimicking peptides (Arg-Lys-Nle-NH2) to get N-
substituted 5-arylidenethiazolidinone-(di/tri)-peptide hybrid constructs (cap-Arg-
Lys-Nle-NH2). These compounds were evaluated for their inhibitory activity on 
DENV NS2B-NS3 protease as presented in Fig.1.8a. Molecular modeling evaluation 
revealed the location of cap region (rhodanine and thiazolidinone) near the 
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hydrophobic region of NS2B cofactor whilst Nle, Lys and Arg residues were located 
in S10, S1 and S2 pockets, respectively (Nitsche et al. (2013)).  
 
In a second example as illustrated in Fig.1.8b, a new class of dipeptides with a 
core moiety of methionine-prolineanilides were developed as potential DENV 
NS2B-NS3 protease inhibitor. It was revealed that for an optimum activity, it is 
necessary to have p-nitrophenyl group, proline with  S-configuration and methionine 
with free amino- and thioether in non-oxidized form (Zhou et al. (2013)). 
 
Figure 1.8 Peptide conjugates active against NS2B-NS3 protease. a ( Nitsche et al. 
(2013)) and b (Timiri et al. (2016)) 
 
1.4.3 Small molecule inhibitors (natural and synthetic) 
Natural products such as 4-hydroxypanduratin A and panduratin A (Table 1.3) were 
also reported to inhibit DENV protease with a Ki of 21 µM and 25 µM against 
DENV NS2B-NS3 protease (Kiat, Pippen, Yusof, & Ibrahim, (2006)). 
 16 
Agathisflavone  and myricetin were observed to be non-competitive inhibitors of 
dengue virus serotype 2 NS2B-NS3 protease with Ki values of 11 and 4.7 μM, 
respectively (de Sousa et al. (2015)). Docking studies propose a binding mode of the 
flavonoids in a particular allosteric binding site (around Gln88, Gln167, and Gly124) 
of the enzyme which is near to its catalytic triad (de Sousa et al. (2015)). 
 
Table 1.3 Natural Product Inhibitors active against NS2B-NS3 protease. 
Compound Name Chemical class Structure Activity (M) Source plant References 
 
DV2 
 
DV3 
Panduratin A Cyclohexenyl 
Chalcone 
derivative 
 
Ki= 25 NA Boesenbergia 
 rotunda (L.)  
Mansf. 
Kiat et al.  
2006 
4-hydroxypanduratin A Cyclohexenyl 
chalcone  
derivative 
 
Ki= 21 NA Boesenbergia 
 rotunda (L.)  
Mansf. 
Kiat et al.  
2006 
Agathisflavone Biflavonoid 
 
Ki = 11.1 Ki = 
 15.3 
 
Cenostigma  
macrophyllum  
Tul. 
de Sousa et 
al.  
2015 
OCH3
HO OH
O
H
OH
HO OH
O
H
O
O
HO OH
O
O
HO
OH
OH
OH
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Quercitrin Flavonoid 
 
Ki = 25.7  
 
Ki = 
 28.0 
 
Byrsonima  
Coccolobifolia  
Kunth 
de Sousa et 
al.  
2015 
Myricetin Flavonoid 
 
Ki = 4.7 
 
Ki =  
25.7 
 
Byrsonima  
coccolobifolia  
Kunth 
de Sousa et 
al.  
2015 
Kaempferol Flavonoid 
 
Ki = 22.3 
 
Ki =  
24.2 
 
Byrsonima  
Coccolobifolia 
 Kunth 
de Sousa et 
al.  
2015 
 
Arylcyanoacrylamide derivatives (Table 1.4) with electrophilic nitrile trap for Ser135 
hydroxyl group was found to be yet another logical approach in designing DENV 
NS2B-NS3 protease inhibitors. Electron-donating groups like hydroxyloramine, 
either at para- or meta-position is essential to have increased potency. It was 
assumed that aryl and amide terminals were accommodated in S1 and S1' pockets, 
respectively (Nitsche, Steuer, & Klein, (2011)). The best compound for this effort 
showed a percentage of inhibition of 46.6 ±1.4  with an IC50 of 50 µM. 
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Table 1.4 Synthetic Inhibitors active against NS2B-NS3 protease 
Chemical class Structure Activities (M) References 
Thiadiazoloacrylamide 
 
IC50 =2.24 Liu et al. 2014 
Imidazophthalazine 
 
IC50 = 6.00  Bodenreider et al. 
2009 
Alkyl ammonium 
 
IC50 = 15.4 Yang et al. 2011 
Arylcyanoacrylamide 
 
Ki  = 98.1 µM* Nitsche et al.,2011 
Arylcyanoacrylamide 
 
Ki  = 35.7 µM* Nitsche et al. 2011 
Arylcyanoacrylamide 
 
Ki  = 184 µM* Nitsche et al. 2011 
Anthracene 
 
Ki = 3.0 Tomlinson a et al., 
2011 
Anthracene 
 
Ki = 10.0 Tomlinson et al., 
2011 
S
NN
N
N
NH
O
N
S
N
N
N
NH
NH2
N
NH
NH2
N
O
O
O
N
N
N
H
O
O
HO
NH2
O
N
N
N
H
O
O
N
O
OH
OH
HO
O
OOH
OH
OH
OH
 19 
Benziimidazole 
 
IC50 = 13.1 Deng et al. 2012 
Quinoline 
 
IC50 = 9.5 Deng et al. 2012 
Quinoline 
 
IC50 = 7.5 Deng et al.,2012 
Aminobenzamide 
 
52.5% at 25 M Aravapali et al. 
2012 
Quinoline 
 
IC50 = 2.4 Lai et al. 2013 
OO
NN
HN NH
N
NH N
NH
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N
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Quinoline 
 
IC50 = 3.5 Lai et al. 2013 
Quinoline 
 
IC50 = 5.2 Lai et al. 2013 
Benzisothiazole 
 
80% at 25 M Lai et al. 2012 
Benzimidazole 
 
IC50 = 6.0 Raut et al. 2015 
 
In a separate initiative, a novel series of thiadiazoloacrylamide analogues as DENV 
NS2B-NS3 protease inhibitors was designed based on the structure of the hit 
obtained through a high-throughput screening of commercially available chemical 
library containing ~7000 compounds which resulted in the discovery of a compound 
with IC50of 2.24 µM against DENV2 NS2B-NS3 protease (Liu et al. (2014)). The 
docked conformation of active compounds from this study shows that the nitrile 
group is involved in hydrogen-bonding interactions with the side chain of Ser83 and 
the main chain of Met84. The benzyl group in these compounds was predicted to 
O
NH
N
N
S
OH
NH
N
N
S
OH
O
S
N
O
N
N
O
OCH3
N
N
H
N
S
HO
O
Cl
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have hydrophobic interactions with residues, including Val154, Val155, Gly159 and 
Ile86. 
 
Attempts have also been made to identify potential lead compounds against DENV 
NS2B-NS3 protease using high-throughput screening (Bodenreider et al. (2009)). 
The best compound from this study with the central phthalazine ring forms a pi–pi 
interaction with the phenyl group of Tyr161. Both charged imidazoline groups are 
involved in salt bridge or hydrogen bonds with several residues (Asp129, Gly159, 
and Asn84). These molecules were found to have good inhibitory effect and has been 
shown by their experimental inhibition values: (a) Ki of 15.43±2.12 µM (Yang et al. 
(2011)), (b) IC50 of 4.2 µM on DENV2 and IC50 of 0.99 µM on DENV3 (Wu et al. 
(2015)), (c) IC50 of 2.0 µM on DENV1, IC50 of 2.3 µM on DENV2, IC50 of 1.6 µM 
on DENV3 and IC50 of 2.0 µM on DENV4 cells (Bodenreider et al. (2009)). In a 
separate study, Deng and co workers discovered benziimidazole class of 
compound was found active against NS2B-NS3 protease (IC50 = 13.12 µM) by 
virtual screening. This study was further continued with scaffold hopping initiatives  
to discover the quinoline class of compounds with IC50 of 7.5 µM. In 2013, Lai and 
co workers (Lai et al. (2013)) reported  8-hydroxyquinoline (HQ) derivatives for 
inhibition of DENV2 protease. The kinetic constant (Ki) for the most potent 8-HQ-
aminobenzothiazole inhibitor from this study with an IC50 value of 0.91 ± 0.05 µM 
was determined to be 2.36 ± 0.13 µM. The mode of action of compounds in this 
work is to inhibit the DENV2 NS2B-NS3pro by a competitive mode of inhibition. 
The best compound  was predicted to be forming favorable hydrophobic interaction 
of the bulkier 8-HQ with three aromatic residues phe130, tyr150 and tyr161 whereas, 
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another active compound from this work with bulkier benzothiazole moiety form 
hydrophobic interaction with val155. 
 
1.4.4 Structure-Based Drug Design (SBDD) 
Understanding the small-molecule ligands binding with therapeutic drug targets 
(proteins) plays a key role in discovery of novel drugs (Blaney, (2012)). structure 
based drug design (SBDD) refers to the rational utilization of structural data from 
macromolecular targets, obtained from x-ray diffraction or through homology 
modeling (Mandal et al., (2009)). The end result of this whole exercise is to discover 
novel molecules with high receptor binding affinity. The availability of three-
dimensional macromolecular structures takes care of the binding site topology, 
including the presence of clefts, cavities and sub-pockets. 
 
Electrostatic properties, such as charge distribution, are also understood. Current 
SBDD methods enable the design of novel molecules consisting of necessary 
features for efficient modulation of the protein target.  Selective binding of a 
validated drug target by high affinity ligand which can interfere with specific cellular 
processes, ultimately leading to the required therapeutic effects (Urwyler, (2011)). 
SBDD is a iterative method consisting of stepwise information gathering.  Starting 
from a known protein structure, computational studies are conducted to identify 
potential ligands. These molecular modeling procedures are followed by the 
experimental synthesis of the most promising candidates (Wilson et al., (2011)). 
Subsequently, evaluations of biological properties, such as potency, affinity and 
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efficacy, are carried out using in-vitro and in-vivo studies (Fang et al., (2012)). 
Provided that active compounds are identified, the crystal  structure of the ligand 
bound receptor complex can be solved. The available structure allows the 
observation of intermolecular physical forces which actually leads the process of 
molecular recognition. Structural descriptions of ligand-receptor complexes are 
utilized for the investigation of binding conformations, characterization of important 
interactions, exploration of unknown binding sites, mechanism of action studies and 
the elucidation of small molecule-induced changes in conformation (Kahsai et al. 
(2011)). 
 
1.4.5 Molecular Docking 
Molecular docking is one of the most frequently used methods in SBDD because of 
its ability to predict the conformation of small-molecule within the appropriate target 
binding site (Xuan-Yu et al., (2011)). Following the development of the first 
algorithms in the eighties, molecular docking has gradually being used as an 
indispensible tool in inhibitor discovery (Lopez-Vallejo et al. (2011)). For example, 
investigations involving ligand binding modes and the corresponding intermolecular 
interactions that stabilize the ligand-receptor complex, can be easily carried out 
(Huang et al., (2010)). In addition to that, molecular docking algorithms execute 
quantitative predictions of binding energy, providing affinity  based ranking order of 
docked compounds. Molecular docking methodology can be conveniently used to 
screen virtual libraries of drug-like molecules in order to obtain leads for further drug 
development. 
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The identification of the most likely binding conformations is carried out two 
steps: (i) exploration of a conformational space with different potential binding 
modes; (ii) accurate prediction of the interaction energy associated with each of the 
predicted binding conformation (Kapetanovic et al., (2008)). Molecular docking 
programs perform these functions through a iterative process, in which the ligand 
conformation is evaluated by specific scoring functions. This entire process is carried 
out repeatedly until it converges to a solution of minimum energy (Huang et al., 
(2010); Kapetanovic et al., (2008); Yurievet al., (2011)). 
 
Content of the Thesis 
This chapter has reviewed the dengue virus from a perspective of epidemiology and 
clinical manifestation. The structure of the dengue virus, specific therapeutic targets 
related to dengue virus, molecular mechanism of dengue virus NS2B-NS3 protease, 
inhibitor development has been discussed in detail.  
In Chapter 2, various methodologies related to inhibitor design, organic synthesis 
and enzyme assay are discussed. In Chapter 3, results and discussions related to 
inhibitor design, organic synthesis and bioassay experiments are elaborated. 
In Chapter 4, conclusion and future studies has been described to take the current 
work forward towards a deeper understanding of the mechanism of the developed 
compounds. 
  
